Fusen Pharmaceutical Company Limited
HKEX:1652.HK
1 (HKD) • At close September 11, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 565.608 | 491.757 | 385.664 | 486.854 | 407.388 | 462.061 | 452.58 | 441.988 | 368.634 |
| Cost of Revenue
| 266.102 | 266.736 | 174.531 | 220.787 | 194.9 | 210.744 | 200.634 | 219.799 | 195.357 |
| Gross Profit
| 299.506 | 225.021 | 211.133 | 266.067 | 212.488 | 251.317 | 251.946 | 222.189 | 173.277 |
| Gross Profit Ratio
| 0.53 | 0.458 | 0.547 | 0.547 | 0.522 | 0.544 | 0.557 | 0.503 | 0.47 |
| Reseach & Development Expenses
| 65.197 | 15.376 | 10.64 | 27.276 | 11.608 | 11.221 | 3.357 | 0.701 | 0.325 |
| General & Administrative Expenses
| 74.898 | 69.921 | 65.235 | 78.874 | 58.729 | 49.304 | 44.98 | 40.277 | 26.039 |
| Selling & Marketing Expenses
| 139.541 | 118.721 | 90.946 | 107.407 | 112.805 | 89.587 | 90.704 | 74.208 | 63.636 |
| SG&A
| 214.439 | 188.642 | 156.181 | 186.281 | 171.534 | 138.891 | 135.684 | 114.485 | 89.675 |
| Other Expenses
| -3.283 | -2.228 | -9.535 | -4.451 | -5.429 | 0.983 | 0.71 | 2.536 | 1.954 |
| Operating Expenses
| 271.455 | 186.414 | 146.646 | 181.83 | 166.105 | 127.709 | 130.476 | 106.133 | 88.378 |
| Operating Income
| 20.016 | 15.738 | 52.137 | 103.217 | 66.148 | 136.067 | 122.18 | 118.592 | 86.853 |
| Operating Income Ratio
| 0.035 | 0.032 | 0.135 | 0.212 | 0.162 | 0.294 | 0.27 | 0.268 | 0.236 |
| Total Other Income Expenses Net
| -50.9 | -46.731 | -28.346 | -24.812 | -2.334 | -12.253 | -5.844 | -3.824 | -29.585 |
| Income Before Tax
| -29.448 | -30.993 | 23.791 | 78.405 | 63.814 | 123.814 | 116.336 | 114.768 | 57.268 |
| Income Before Tax Ratio
| -0.052 | -0.063 | 0.062 | 0.161 | 0.157 | 0.268 | 0.257 | 0.26 | 0.155 |
| Income Tax Expense
| 6.847 | 3.661 | 7.178 | 15.737 | 11.555 | 21.905 | 19.285 | 18.57 | 11.233 |
| Net Income
| -36.277 | -34.654 | 16.645 | 70.131 | 53.434 | 101.882 | 96.82 | 95.073 | 44.879 |
| Net Income Ratio
| -0.064 | -0.07 | 0.043 | 0.144 | 0.131 | 0.22 | 0.214 | 0.215 | 0.122 |
| EPS
| -0.05 | -0.046 | 0.02 | 0.09 | 0.067 | 0.15 | 0.12 | 0.12 | 0.056 |
| EPS Diluted
| -0.048 | -0.046 | 0.02 | 0.09 | 0.067 | 0.15 | 0.12 | 0.12 | 0.056 |
| EBITDA
| 44.014 | 49.899 | 86.836 | 125.674 | 75.354 | 144.746 | 161.141 | 169.619 | 114.72 |
| EBITDA Ratio
| 0.078 | 0.101 | 0.225 | 0.258 | 0.185 | 0.313 | 0.356 | 0.384 | 0.311 |